Business
Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
NASHVILLE, Tenn., November 12, 2025--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squibb (NYSE: BMY), a leading biopharmaceutical company, today announced an expanded strategic collaboration aimed at accelerating the development of innovative cancer therapies and increasing access to clinical trials for patients across the U.S.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1484,"height":255,"url":"https://media.zenfs.com/en/business-wire.com/3915a7eb2c49f6acdae24e43bf4545a0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JRdZ4Em5VBGn3KxFOCEKVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3915a7eb2c49f6acdae24e43bf4545a0","width":960,"height":165},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/PebuBh7l3SEFUgVCJ7_GRw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3915a7eb2c49f6acdae24e43bf4545a0","width":1200,"height":206}},"lazy":false},{"type":"text","content":"Collaboration Leverages Data-Driven Approach to Bring Cutting-Edge Clinical Trials to More Communities","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"NASHVILLE, Tenn., November 12, 2025--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, and Bristol Myers Squibb (NYSE: BMY), a leading biopharmaceutical company, today announced an expanded strategic collaboration aimed at accelerating the development of innovative cancer therapies and increasing access to clinical trials for patients across the U.S.","length":462,"tagName":"p"},{"type":"text","content":"Central to the collaboration is SCRI’s Accelero, a next-generation clinical trial delivery model that streamlines operations and accelerates trial execution across SCRI’s expansive network of more than 200 locations. By aligning Bristol Myers Squibb’s pioneering oncology pipeline with SCRI’s research infrastructure and expertise, the collaboration is designed to bring cutting-edge research directly to patients—where they live and receive care.","length":447,"tagName":"p"},{"type":"text","content":""At Bristol Myers Squibb, we recognize that accelerating clinical trial enrollment requires not only scientific innovation but also operational innovation. This includes a deep commitment to equity and inclusion, while we look to accelerate overall patient enrollment," said Mokash Sharma, Senior Vice President, Global Development Operations, Bristol Myers Squibb. "Improving access to clinical research isn’t just abo...